U.S. Treasury Building

The U.S. Treasury Department, shown in a file photo above, plans to sell $3 billion of its stock in Ally Financial, a Detroit-based lender that the government bailed out during the financial crisis. (Chip Somodevilla / Getty Images / March 23, 2009)

  • Also
  • Ally Financial pays $98 million to settle auto lending bias probe Ally Financial pays $98 million to settle auto lending bias probe
  •  GM said to be planning sale of its stake in Ally Financial GM said to be planning sale of its stake in Ally Financial
  • Freddie Mac to pay U.S. $30.4 billion, offsetting bailout cost Freddie Mac to pay U.S. $30.4 billion, offsetting bailout cost
  • Treasury secretary improves his penmanship for currency signature Treasury secretary improves his penmanship for currency signature

The wind-down of the bailout continues.

The Obama administration has decided to sell about $3 billion of the government’s common stock holdings in Ally Financial Inc., a former General Motors Corp. lending arm propped up with taxpayer assistance during the financial crisis.

That would bring the recovery from Ally to $15.3 billion, or 89%, of the $17.2 billion bailout provided by the Troubled Asset Relief Program, the Treasury Department said Thursday in announcing its plan.

QUIZ: big business news of 2014

The deal would involve unloading 410,000 shares of Ally common stock at $7,375 apiece in a private offering, the department said. After the sale, taxpayers would still hold about 37% of Ally’s common stock, a stake the government plans to sell later.

The transaction would bring the Treasury Department's total recovery on the various TARP bailout efforts to $435.8 billion, exceeding the $422.2 billion disbursed. 

Ally, based in Detroit, was founded in 1919 as General Motors Acceptance Corp. to provide financing for buyers of GM vehicles. At the time of the financial crisis it had run up enormous losses at a subprime mortgage arm.

ALSO:

Betty Ford Center ready for a comeback

Americans are drinking less coffee daily, study says

U.S. lawmakers ask Gilead to justify hepatitis C drug's $84,000 price